February Webinar: The Real-World Use of Combined P-glycoprotein and Moderate CYP3A4 Inhibitors with Rivaroxaban or Apixaban Increases Bleeding
Please join us for our February webinar on the following study: Combined Pgp- and moderate CYP3A4 inhibitors such as amiodarone and diltiazem are commonly prescribed with apixaban and rivaroxaban, however little is known about the clinical importance of this drug–drug interaction. The aim of this study was to compare the occurrence of bleeding in patients taking apixaban or rivaroxaban with and without a combined P-gp and moderate CYP3A4 inhibitor in a real-world setting on Feb 27, 2020 12:00 PM ET. Register Now
FREE CE | Anticoagulation Forum Webinars
Through our partnership with freeCE, we now offer credit for our select webinars. If you participated in these webinars live, you may now go to the AC Forum freeCE landing page and get pharmacy and nursing continuing education credit for those webinars.You will need to create an account with freeCE to access the programs. There is no cost to register.
Supporting Implementation of New Joint Commission NPSG
The Joint Commission National Patient Safety Goal related to anticoagulant therapy has been updated with 6 new Elements of Performance (EPs). The AC Forum has indexed our resources as they relate to each EP and created a Centers of Excellence Resource Center new section: NPSG Elements, listed under the Quality Improvement menu on the left side. Here you’ll find:
- Downloadable Search Instructions for NPSG Tools
- Compendium of Resources by Joint Commission to support implementation
- Anticoagulant Therapy Webinar Series by Joint Commission and Anticoagulation Forum
FDA-funded Anticoagulation Stewardship Guide
Download our new FDA-funded release, Core Elements of the Anticoagulation Stewardship Program, which outlines systemic protocols designed to improve the safety and quality of care for patients and reduce the adverse drug effects related to anticoagulant medications.
